229 related articles for article (PubMed ID: 30917298)
21. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
[TBL] [Abstract][Full Text] [Related]
22. Whole exome sequencing and system biology analysis support the "two-hit" mechanism in the onset of Ameloblastoma.
Shi Y; Li M; Yu Y; Zhou Y; Wang S
Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e510-e517. PubMed ID: 33395399
[TBL] [Abstract][Full Text] [Related]
23. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
[TBL] [Abstract][Full Text] [Related]
24. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
[TBL] [Abstract][Full Text] [Related]
25. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
26. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
[TBL] [Abstract][Full Text] [Related]
27. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic study on a rare variant of ameloblastoma with basal cell features.
You Z; Sun L; Yan X; Zhang J; Du J; Li T; Zhao H
Oral Dis; 2019 Apr; 25(3):788-795. PubMed ID: 30561173
[TBL] [Abstract][Full Text] [Related]
29. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.
Bartels S; Adisa A; Aladelusi T; Lemound J; Stucki-Koch A; Hussein S; Kreipe H; Hartmann C; Lehmann U; Hussein K
Virchows Arch; 2018 Jun; 472(6):1055-1059. PubMed ID: 29546640
[TBL] [Abstract][Full Text] [Related]
30. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
[TBL] [Abstract][Full Text] [Related]
31. Machine learning-based radiomics for predicting BRAF-V600E mutations in ameloblastoma.
Li W; Li Y; Liu X; Wang L; Chen W; Qian X; Zheng X; Chen J; Liu Y; Lin L
Front Immunol; 2023; 14():1180908. PubMed ID: 37646022
[TBL] [Abstract][Full Text] [Related]
32. Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst.
Cha YH; Cho ES; Kang HE; Ko J; Nam W; Kim HJ; Kim NH; Kim HS; Cha IH; Yook JI
Oral Oncol; 2017 Nov; 74():62-67. PubMed ID: 29103753
[TBL] [Abstract][Full Text] [Related]
33. Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis.
Togni L; Zizzi A; Mazzucchelli R; Santarelli A; Rubini C; Mascitti M
Int J Oral Sci; 2022 Apr; 14(1):22. PubMed ID: 35468886
[TBL] [Abstract][Full Text] [Related]
34. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
35. Adenoid ameloblastoma harbors beta-catenin mutations.
Bastos VC; Coura BP; Guimarães LM; Fernandes BG; Chan AC; Vargas PA; Bastos-Rodrigues L; De Marco LA; Hellstein J; Thavaraj S; Wright JM; Odell EW; Gomez RS; Gomes CC
Mod Pathol; 2022 Nov; 35(11):1562-1569. PubMed ID: 35840721
[TBL] [Abstract][Full Text] [Related]
36. Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta-analysis.
Martins-de-Barros AV; Silva CCG; Gonçalves KKN; de Albuquerque Cavalcanti Almeida R; de Oliveira E Silva ED; da Costa Araújo FA; Robinson L; van Heerden WFP; de Vasconcelos Carvalho M
J Oral Pathol Med; 2023 Sep; 52(8):701-709. PubMed ID: 37364158
[TBL] [Abstract][Full Text] [Related]
37. BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology.
Brunner P; Bihl M; Jundt G; Baumhoer D; Hoeller S
Oral Oncol; 2015 Oct; 51(10):e77-8. PubMed ID: 26306423
[No Abstract] [Full Text] [Related]
38. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
[TBL] [Abstract][Full Text] [Related]
39. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
[TBL] [Abstract][Full Text] [Related]
40. Differential Profile of Primary and Recurrent Ameloblastomas Among Afro-descendants and Non-Afro-descendants-a Systematic Review.
Patel P; Effiom OA; Akinshipo AO; Akintoye SO
J Racial Ethn Health Disparities; 2024 Feb; 11(1):92-100. PubMed ID: 36596981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]